NCT00619541View on ClinicalTrials.gov

Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

January 31, 2009

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Infusional 5-Fluorouracil

5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.

DRUG

Sorafenib (Bay 43-9006)

Sorafenib 400 mg bid orally continuously. Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease.

Trial Locations (1)

56100

Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina ... Indirizzo: via Roma, 55 - 56100 Pisa Tel. 050-2218690 - Fax. 050-2218685, Pisa

All Listed Sponsors
lead

Italian Trial in Medical Oncology

OTHER

NCT00619541 - Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter